25CN‐NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor

@article{MrcherRrsted202125CNNBOHAS,
  title={25CN‐NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor},
  author={Emil M{\"a}rcher R{\o}rsted and Anders A. Jensen and Jesper L. Kristensen},
  journal={ChemMedChem},
  year={2021},
  volume={16}
}
4‐(2‐((2‐hydroxybenzyl)amino)ethyl)‐2,5‐dimethoxybenzonitrile (25CN‐NBOH) was first reported as a potent and selective serotonin 2A receptor (5‐HT2AR) agonist in 2014, and it has since found extensive use as a pharmacological tool in a variety of in vitro, ex vivo and in vivo studies. 25CN‐NBOH is readily available from a synthetic perspective using standard chemical transformations, and displays favorable physiochemical properties in terms of stability and solubility. Due to its superior… 
View on Wiley
ncbi.nlm.nih.gov

References

SHOWING 1-10 OF 52 REFERENCES
A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain.
The selective 5-HT2A receptor agonist 25CN-NBOH: structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH.
Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties of N-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT2A Receptor Agonist
TLDR
25CN-NBOH appears to be a superior selective and brain-penetrant 5-HT2A receptor agonist compared with (±)-2,5-dimethoxy-4-iodoamphetamine (DOI), and it is proposed that the compound could be a valuable tool for future investigations of physiologic functions mediated by this receptor.
Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability
TLDR
It is hypothesized that the low hepatic stability of the N-benzylated phenethylamines renders them orally inactive due to first pass metabolism, which is supported by anecdotal data from recreational use of these compounds.
Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
TLDR
The major CYP enzymes involved in the metabolism of 25I-NBOMe and 25INBOH were identified as CYP3A4 and CYP2D6, respectively.
In vitro autoradiography of serotonin 5‐HT2A/2C receptor‐activated G protein: Guanosine‐5′‐(γ‐[35S]thio)triphosphate binding in rat brain
TLDR
Autoradiography revealed a similar localization of DOI‐ and 5‐HT‐stimulated binding of [35S]GTPγS in distinct areas of prefrontal and parietal cortex, consistent with previously reported 5‐ HT2A receptor distribution.
Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.
TLDR
A series of 48 compounds with structural variations in both the phenethylamine and N-benzyl part of the molecule are prepared to determine the effects on receptor binding affinity and functional activity at 5- HT2A and 5-HT2C receptors.
Neurochemical pharmacology of psychoactive substituted N‐benzylphenethylamines: High potency agonists at 5‐HT2A receptors
Synthesis and evaluation of (18)F-labeled 5-HT2A receptor agonists as PET ligands.
A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug
TLDR
A case of self-reported exposure to 25-I (25I-NBOMe), a novel phenethylamine derivative, with subsequent quantification in serum is described, a potent new synthetic drug with apparent significant behavioral toxicity that can be detected and quantified in serum.
...
...